MAPT and early-onset autosomal dominant Alzheimer disease: This revealed tracer binding to tissue from cases with Alzheimer’s disease (Fig. 2–5) and the FTDP-17 case with the R406W MAPT mutation (Fig. 6), but not to cases with Pick’s disease, progressive supranuclear palsy, corticobasal degeneration, and FTDP-17 with Δ280K or 10 + 16 MAPT mutation (Additional file 1: Figure S2).